Home Clinical Topics FDA approves new daily treatment for RLS

FDA approves new daily treatment for RLS

The U.S. Food and Drug Administration has approved Horizant Extended Release Tablets (gabapentin enacarbil) as a daily treatment for moderate-to-severe restless legs syndrome (RLS). Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250188.htm.

LEAVE A REPLY

Please enter your comment!
Please enter your name here